Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 mass balance and pharmacokinetics study of intravenous [14C]-TAK-954 in healthy male subjects
NL-OMON46703Phase 1Active, not recruiting
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of felcisetrag in Gastrointestinal Dysmotility, sponsored by Millennium Pharmaceuticals. Primary endpoints: Mass balance and routes of elimination, Metabolic profiling and metabolite identification and 1 more. Started Apr 2018; status: active, not recruiting.
02
Drugs
felcisetrag
03
Conditions
Gastrointestinal Dysmotility
Beyond the preview
Go deeper on NL-OMON46703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46703.